| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Azido-PEG4-CH2CO2-t-Bu is a non-cleavable linker for bio-conjugation containing an Azide group. It is a PEG-based PROTAC linker used in the synthesis of PROTACs (proteolysis-targeting chimeras). The compound has an Azide (N3) moiety that can undergo CuAAC (copper-catalyzed azide-alkyne cycloaddition) click chemistry with compounds bearing an Alkyne group. The tert-butyl ester (Boc) group provides protection for the carboxylic acid functionality.
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1]. Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system [2].
In vitro, Azido-PEG4-CH2CO2-t-Bu is used as a building block for the synthesis of PROTACs and other bioconjugates. The compound's azide group enables efficient click chemistry conjugation. The PEG spacer enhances the solubility and stability of the resulting conjugates. As a non-cleavable linker, it provides stable conjugation between the target protein ligand and the E3 ligase ligand in PROTACs. The compound's tert-butyl ester can be deprotected to reveal a carboxylic acid for further conjugation. |
| ln Vivo |
In vivo, Azido-PEG4-CH2CO2-t-Bu is not administered directly but is used to synthesize PROTACs that are evaluated in animal models. The PEG spacer enhances the solubility and stability of the resulting PROTACs. The compound's role as a linker in PROTAC synthesis has been validated in various preclinical studies. The resulting PROTACs enable targeted protein degradation, representing a novel therapeutic modality for various diseases.
|
| Enzyme Assay |
In cell-free biochemical assays, Azido-PEG4-CH2CO2-t-Bu is evaluated for its ability to serve as a linker in conjugation reactions. The azide group enables efficient CuAAC click chemistry with alkyne-bearing molecules. The compound's purity (≥95%) and molecular weight (333.4 g/mol) are characterized using analytical techniques. The compound's solubility and stability in various solvents are assessed to ensure compatibility with conjugation reactions.
|
| Cell Assay |
Cellular assays for Azido-PEG4-CH2CO2-t-Bu involve evaluating the activity of the PROTACs synthesized using this linker. The resulting PROTACs are tested for their ability to degrade target proteins in cell lines. The PEG linker's effect on cellular uptake, intracellular trafficking, and protein degradation activity is assessed. The compound itself is not biologically active and serves only as a linker.
|
| Animal Protocol |
Animal models for Azido-PEG4-CH2CO2-t-Bu involve evaluating the PROTACs synthesized using this linker in preclinical studies. The resulting PROTACs are tested in disease models relevant to the target protein. The PEG linker's effect on pharmacokinetics, biodistribution, and efficacy is assessed. The compound's role in enabling targeted protein degradation has been demonstrated in various preclinical studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Azido-PEG4-CH2CO2-t-Bu are not typically reported as the compound is a linker rather than a therapeutic agent. The compound's molecular weight is 333.4 g/mol with a formula of C14H27N3O6. The CAS number is 864681-04-9. The compound is soluble in organic solvents typical for PEG-containing molecules. Standard handling procedures for PEG linkers apply. The compound should be stored at -20°C.
|
| Toxicity/Toxicokinetics |
Toxicity data for Azido-PEG4-CH2CO2-t-Bu are limited as the compound is a linker rather than a therapeutic agent. The compound is supplied at ≥95% purity. Standard safety precautions for handling laboratory chemicals apply. The azide group may pose a hazard if heated or subjected to shock, as azides can be explosive. The compound is for research use only and not for human use.
|
| References |
[1]. Shiladitya Sengupta, et al. Targeted drug delivery through affinity based linkers. WO2015148126A1.
[2]. Zhang F, et al. Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228. |
| Additional Infomation |
Azido-PEG4-CH2CO2-t-Bu is a non-cleavable linker for bio-conjugation that contains an Azide group. It is a PEG-based PROTAC linker used in the synthesis of PROTACs. The compound has an Azide (N3) moiety that can undergo CuAAC click chemistry. The tert-butyl ester provides protection for the carboxylic acid functionality. The compound is used in medical research, drug delivery, nanotechnology, and new materials research. The CAS number is 864681-04-9.
|
| Molecular Formula |
C14H27N3O6
|
|---|---|
| Molecular Weight |
333.381
|
| Exact Mass |
333.19
|
| CAS # |
864681-04-9
|
| PubChem CID |
59465087
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
1.157
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
23
|
| Complexity |
353
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[N-]=[N+]=NCCOCCOCCOCCOCC(OC(C)(C)C)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9996 mL | 14.9979 mL | 29.9958 mL | |
| 5 mM | 0.5999 mL | 2.9996 mL | 5.9992 mL | |
| 10 mM | 0.3000 mL | 1.4998 mL | 2.9996 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
